PEPTIDE GUIDE

What Is MOTS-c?

MOTS-c is a 16-amino-acid peptide first reported in 2015. Its sequence is encoded within mitochondrial DNA, the small set of genetic material found inside the parts of cells that help produce usable energy.

Researchers have studied MOTS-c as a possible signal involved in metabolism, insulin sensitivity, exercise and the response to cellular stress. Most evidence for administering the peptide comes from cells and animals. Human studies have mainly measured the body's own MOTS-c, although a Phase 2 trial of synthetic MOTS-c began in 2026 and has not yet reported results.

Research statusEarly human research; no approved medical use
Peptide sequenceMRWQEMGYIFYPRKLR
Peptide typeSixteen-amino-acid mitochondrial-derived peptide
Human evidenceEarly clinical research
Last reviewed17 November 2026
THE SHORT ANSWER

MOTS-c is a short peptide linked to mitochondrial genetic material. The original 2015 study found that synthetic MOTS-c changed cell metabolism and reduced diet-related weight gain and insulin resistance in mice. A later study found that the body's own MOTS-c increased in the muscle and blood of ten healthy young men after exercise, while the claimed improvements in physical performance came from mice given the peptide. Human measurement studies do not prove that administering MOTS-c improves metabolism, fitness or ageing. One Phase 2 trial is now testing native MOTS-c in people, but it has no published results. MOTS-c is not approved by the US Food and Drug Administration, normally shortened to FDA, and is prohibited at all times for athletes governed by World Anti-Doping Agency rules.

What does MOTS-c stand for?

MOTS-c stands for mitochondrial open reading frame of the 12S ribosomal RNA type-c.

An open reading frame is a stretch of genetic code that can be read to make a peptide or protein. Ribosomal RNA is normally known for helping cells build proteins. The surprise was that a short sequence inside the mitochondrial 12S ribosomal RNA gene appeared to encode a biologically active peptide as well.

The final “c” was used during the search for possible short open reading frames. It is part of the name and does not refer to vitamin C.

What are mitochondria?

Mitochondria are structures inside most human cells. They convert energy from nutrients into adenosine triphosphate, normally shortened to ATP. ATP is a molecule that cells can use to power chemical work.

Mitochondria contain a small circular genome separate from most DNA in the cell nucleus. A genome is the complete set of genetic instructions in that location. Human mitochondrial DNA contains 16,569 pairs of DNA letters and was traditionally described as encoding 13 larger proteins, 22 transfer RNAs and two ribosomal RNAs.

MOTS-c belongs to a proposed group called mitochondrial-derived peptides. These short peptides may allow mitochondria to send information about energy and stress to the rest of the cell. The category describes biological origin. It does not make a synthetic product a proven medicine.

What is the difference between endogenous and synthetic MOTS-c?

Endogenous MOTS-c is the peptide proposed to be produced within the body. Synthetic MOTS-c is a chemically assembled version used in experiments. The intended 16-amino-acid sequence can be the same, but the two terms answer different questions.

Measuring endogenous MOTS-c can show that the concentration in blood or tissue changes with exercise, age or disease. It cannot show what happens when a manufactured amount is introduced from outside the body. Natural production may be local, brief and linked to other cell signals. External administration creates a different pattern of exposure.

Synthetic identity is also not the same as product equivalence. A clinical trial controls the peptide sequence, impurities, formulation, sterility, storage and batch consistency. An online vial carrying the same name has not necessarily met those controls.

This boundary is central to the evidence. Most human MOTS-c papers are measurement studies of the body's own peptide. The performance, weight and metabolism experiments that involved administered native MOTS-c were mainly conducted in mice.

What is MOTS-c made from?

MOTS-c contains 16 amino acids with the sequence methionine, arginine, tryptophan, glutamine, glutamic acid, methionine, glycine, tyrosine, isoleucine, phenylalanine, tyrosine, proline, arginine, lysine, leucine and arginine. The one-letter form is MRWQEMGYIFYPRKLR.

An amino acid is a building block used to make peptides and proteins. MOTS-c is linear, meaning the chain is not closed into a ring. It does not carry the fatty-acid side chain found on some long-acting metabolic peptides.

The human body and a chemical manufacturer can produce the same amino-acid sequence by very different routes. Cells use genetic information and ribosomes. A laboratory joins prepared amino-acid building blocks through controlled chemical reactions.

When was MOTS-c first documented?

A research team led by Changhan Lee and Pinchas Cohen at the University of Southern California first described MOTS-c in a peer-reviewed paper published in March 2015. The study reported the sequence, detection in tissues and blood, effects on cell metabolism and findings in mice.

The mitochondrial genome itself had been fully sequenced decades earlier. What changed in 2015 was the interpretation of one region: researchers proposed that a short sequence within the 12S ribosomal RNA gene could produce a signalling peptide.

In 2018, the same wider research programme reported that MOTS-c could move into the cell nucleus during metabolic stress and alter gene activity. In 2021, researchers reported an increase in endogenous MOTS-c after exercise in ten men and administered synthetic peptide to mice of different ages. Endogenous means made within the body.

CohBar, Inc., a US biotechnology company created to develop medicines based on mitochondrial peptides, tested a modified MOTS-c analogue called CB4211 in a Phase 1 programme. An analogue is a related but chemically different molecule. Its findings cannot be treated as clinical results for native MOTS-c.

In February 2026, a separate Phase 2a study called MOTS-MET began. Phase 2 trials ask whether an investigational medicine appears to work in people with the target condition while continuing safety assessment. The “a” indicates an earlier, exploratory part of that stage. The study is expected to include 120 adults and had not published results when this guide was reviewed.

YearWhat was documented
2015MOTS-c was first described as a 16-amino-acid mitochondrial-derived peptide
2018Cell and animal research reported movement into the nucleus during metabolic stress
2019 to 2021The modified analogue CB4211 entered and completed early clinical research
2021A study measured endogenous MOTS-c after exercise in ten men and tested administered MOTS-c in mice
2026The MOTS-MET Phase 2a trial of native MOTS-c began recruiting adults with prediabetes and overweight or obesity

How does the body make MOTS-c?

The proposed natural process starts with a short open reading frame inside the mitochondrial 12S ribosomal RNA gene, known as MT-RNR1. DNA is copied into an RNA message. Because the sequence is read using the standard genetic code rather than the specialised code normally used inside mitochondria, researchers propose that translation occurs on ribosomes in the cell's cytoplasm. Translation is the process that reads RNA and joins amino acids into a chain.

Research has detected MOTS-c in several tissues and in the circulation. Questions remain about how production is controlled, how the peptide leaves the cell, which measurements are most reliable and whether every observed signal comes from the proposed mitochondrial sequence.

These open questions are normal for a recently discovered biological signal. They are also a reason to avoid presenting the pathway as settled.

Why is MOTS-c unusual in genetics?

The proposed coding sequence sits inside a gene traditionally classified as ribosomal RNA rather than a protein-coding gene. Short open reading frames can be missed by older annotation methods because researchers historically focused on longer proteins.

There is an additional complication. Mitochondria use a slightly different genetic code from the one used in the cell cytoplasm. If the MOTS-c sequence were translated using the mitochondrial code, one of its triplets would be read as a stop signal and the complete proposed peptide would not be produced. The discovery team therefore proposed that the RNA message leaves the mitochondrion and is read by cytoplasmic ribosomes using the standard code.

Research has detected a molecule matching MOTS-c with antibody-based tests and mass spectrometry. Mass spectrometry separates and identifies molecules partly by mass. These findings support the proposed peptide, but questions remain about where translation occurs, how much is produced in different tissues and how measurements from different assays compare.

This is an active biological question, not a reason to dismiss the peptide. It is also why simple statements such as “mitochondria make MOTS-c” need qualification.

How is synthetic MOTS-c manufactured?

Synthetic MOTS-c used in research is normally made by solid-phase peptide synthesis, shortened to SPPS. It is not collected from human muscle or isolated from mitochondria.

The raw peptide materials are protected forms of the amino acids in the 16-position sequence. They include methionine, arginine, tryptophan, glutamine, glutamic acid, glycine, tyrosine, isoleucine, phenylalanine, proline, lysine and leucine. Repeated amino acids require more than one equivalent building block during manufacture. The process also uses a solid resin, coupling chemicals, protecting-group reagents and solvents.

The first protected amino acid is fixed to resin beads. Chemists remove one temporary protecting group, add the next amino acid and repeat the process until the chain is complete. Protecting groups cover reactive parts of the building blocks so that they join at the intended position.

The peptide is then released from the resin and the remaining protecting groups are removed. The crude mixture includes the complete sequence, shorter failed sequences and reaction by-products. Preparative high-performance liquid chromatography, or HPLC, can separate them. Mass spectrometry checks molecular mass, while analytical HPLC estimates purity.

For use in a clinical trial, manufacture also requires validated control of identity, chemical variants, residual solvents, microorganisms, bacterial toxins and batch consistency. Synthetic MOTS-c with the correct sequence may still differ from a trial product if its impurities, formulation and quality controls differ.

This overview is not a synthesis protocol. It excludes reagent quantities, reaction conditions, temperatures, timings, equipment settings, sterile filling and instructions for preparing a product for administration.

How might MOTS-c work?

The most discussed pathway involves AMP-activated protein kinase, normally shortened to AMPK. AMPK is an enzyme that helps cells sense low available energy and adjust how they use or store nutrients.

The 2015 study found that MOTS-c altered the folate-methionine cycle and purine synthesis in cultured cells. These are networks of chemical reactions used to make DNA building blocks and manage cellular metabolism. The changes increased a molecule called AICAR, which can activate AMPK.

Researchers found that MOTS-c encouraged cells to use glucose through pathways that do not require insulin. Insulin is the hormone that normally helps cells take up glucose from the blood. This result led to research on insulin resistance, a state in which cells respond less effectively to insulin.

In 2018, cell experiments reported that metabolic stress caused MOTS-c to move into the nucleus, the compartment containing most cellular DNA. There it appeared to affect the activity of genes involved in stress responses. Gene expression describes how actively a cell uses a gene's instructions.

These mechanisms were investigated in cells and animals. They do not show that administering MOTS-c produces a useful or safe effect in people.

What did the original 2015 study find?

The discovery paper contained cell experiments, tissue measurements and animal work. In cultured cells, synthetic MOTS-c changed pathways involved in glucose use and activated AMPK.

In mice fed a high-fat diet, researchers reported that administered MOTS-c reduced weight gain despite similar food intake and improved the response to insulin. The study also reported improved glucose handling in older mice. Glucose handling describes how efficiently blood glucose rises and returns after the body is challenged with sugar.

These are preclinical findings. Preclinical means research conducted before adequate testing as a treatment in humans. A high-fat-diet mouse model reproduces selected features of metabolic stress but not the full biology, behaviour and medical history of a person with obesity or type 2 diabetes.

The study administration level was 5 milligrams per kilogram of mouse body weight per day. A milligram is one-thousandth of a gram, and per kilogram means the research amount was adjusted to body weight. This animal level cannot be converted into a personal human dose and is included only to describe the experiment.

What can the original mouse model not tell us?

The high-fat-diet model creates metabolic stress over a controlled period in genetically similar mice. Human obesity and type 2 diabetes develop through varied combinations of genetics, food environment, sleep, medicines, illness, physical activity and social conditions.

The mouse study measured weight gain and responses to glucose and insulin. It did not test whether MOTS-c prevented heart attacks, kidney disease, sight loss or early death. It also did not establish a safe long-term human exposure.

Amounts expressed per kilogram cannot be converted by simply multiplying them by human body weight. Species differ in metabolism, body-surface area, receptor biology and how a peptide is broken down. Even formal animal-to-human scaling produces only a starting estimate for controlled development, not a personal administration level.

The original study was important because it linked a proposed mitochondrial peptide with measurable metabolic effects. Its correct role is to justify further research, not to act as a human weight-loss trial.

What did the 2021 exercise study find in people?

The human part included ten sedentary, healthy young men with an average age of about 24.5. They exercised on a stationary bicycle. Researchers collected blood before, during and after exercise, and collected muscle samples before and after.

MOTS-c measured in muscle increased about 11.9-fold after exercise and remained above the starting measurement after four hours of rest. Circulating MOTS-c increased about 1.6-fold during exercise and 1.5-fold afterwards, then returned to baseline after four hours.

This was a small before-and-after measurement study. The men were not given synthetic MOTS-c. There was no placebo group and no test of whether administered peptide improved their performance. The study shows an association between exercise and measured endogenous MOTS-c, not that MOTS-c can replace exercise.

An assay is a laboratory method used to measure a substance. The researchers used western blotting in muscle and an enzyme-linked immunosorbent assay, or ELISA, in blood. Both depend on antibodies recognising the target, so measurement accuracy and specificity remain important.

Do all human exercise studies report the same pattern?

No. Another study collected muscle and blood before and after endurance or resistance exercise and measured both MOTS-c and humanin, another mitochondrial-derived peptide. It found clearer increases for humanin than for MOTS-c in some comparisons.

Different exercise protocols, sampling times, participant characteristics and assays can produce different results. A peptide may rise briefly and return towards its starting level before the next sample. Antibodies used in an assay can also recognise related molecules or differ in sensitivity.

This does not mean one study must be wrong. It means the size and timing of the exercise response are not yet defined well enough to treat circulating MOTS-c as a simple fitness score.

Most importantly, both studies measured endogenous peptides. Neither established that giving synthetic MOTS-c reproduces the health effects of exercise.

What did the same study find in mice?

The performance findings came from mice given synthetic MOTS-c. Researchers tested young, middle-aged and old animals using treadmills and other physical tasks. Some treated groups ran farther or performed better than controls.

In one experiment, young mice received 5 or 15 milligrams per kilogram per day for two weeks. In a high-fat-diet group, all mice at the higher level reached the fastest treadmill stage, compared with 16.6% in the lower-level and control groups. These are animal administration levels and cannot be read as human guidance.

Late-life intermittent treatment improved grip strength, stride length and a walking test in old mice. The lifespan curve did not show a statistically reliable overall extension. A result can improve a measure of healthspan, meaning time lived with better function, without proving a longer lifespan.

The study is relevant to ageing research but does not show that MOTS-c slows ageing in people.

Has MOTS-c itself been tested as a medicine in people?

The MOTS-MET study, registered as NCT07505745, is designed to test native MOTS-c in people. It is a randomised, double-blind, placebo-controlled Phase 2a trial planned for about 120 adults aged 18 to 65 with prediabetes and overweight or obesity.

Prediabetes means blood glucose is above the usual range but not high enough for a diagnosis of type 2 diabetes. Participants are assigned by chance to MOTS-c or placebo for 12 weeks and followed for safety to week 16. Double-blind means neither participants nor the main study team know the assignment during the comparison period. A placebo is an inactive product designed to resemble the study medicine.

The main outcome is an insulin-sensitivity index calculated from an oral glucose tolerance test. In this test, a measured glucose drink is followed by blood samples. The index estimates how effectively the body responds to insulin.

The study began on 2 February 2026 and the registry listed it as recruiting when this guide was reviewed. Its estimated primary completion is February 2027 and final completion is scheduled later. Estimated dates can change.

Participants receive 12 weeks of MOTS-c or placebo alongside standardised lifestyle counselling and are followed to week 16 for safety. The record describes a fixed daily research regimen but does not publish the numeric administration level. Secondary outcomes include HbA1c, fasting glucose, two-hour glucose after the oral test and antibodies against the investigational peptide.

Anti-drug antibodies are immune proteins that recognise a medicine. Their presence can alter how a biological medicine works or, in some cases, contribute to reactions. Measuring them is part of establishing whether repeated exposure produces an immune response.

Recruitment or trial registration is not evidence that the treatment works. Until results are completed, analysed and published, the study adds a development milestone rather than a clinical benefit.

The registry does not publicly state the numeric administration level. This guide does not infer one from products sold online.

What was the CB4211 trial?

CB4211 is a chemically modified analogue of MOTS-c developed by CohBar, Inc. It is related to the native sequence but is not the same molecule.

The Phase 1a and 1b programme enrolled healthy volunteers and people with obesity and non-alcoholic fatty liver disease. This older term describes excess liver fat not primarily caused by heavy alcohol use. Current medical terminology increasingly uses metabolic dysfunction-associated steatotic liver disease, shortened to MASLD.

Phase 1 focuses mainly on initial safety, tolerability and how the body handles a medicine. The study record and company report described injection-site reactions and short-term changes in liver enzymes and metabolic measurements. A 28-day comparison in 20 participants was far too small and short to establish treatment of liver disease.

Most importantly, any safety or efficacy signal belongs to CB4211. It cannot be transferred directly to native MOTS-c.

What do other human studies tell us?

Several studies have measured circulating MOTS-c in people with metabolic, cardiovascular or age-related conditions. Some report higher levels and others lower levels compared with selected control groups.

These are biomarker studies. A biomarker is a biological measurement associated with a condition or process. An association does not establish cause. A lower measurement could contribute to a condition, result from it or reflect another factor such as age, body composition, medicines or physical activity.

Measurement methods and participant populations also vary. These studies can identify questions for clinical trials, but they do not show that giving synthetic MOTS-c will correct a disease.

What has been measured across age groups?

One study compared healthy men aged 18 to 30, 45 to 55 and 70 to 81. Circulating MOTS-c was lower in the older groups, but the amount measured in skeletal muscle was about 1.5 times higher in middle-aged and older men than in the young group.

This apparently opposite pattern shows why blood and tissue measurements cannot be treated as interchangeable. Higher muscle expression could reflect local production, altered release, slower breakdown or adaptation to age-related stress. The study could not determine which explanation was correct.

It also included men only and observed groups at one point in time. A cross-sectional study compares different people rather than following the same individuals as they age. Differences between groups may therefore reflect factors other than ageing itself.

The result does not show that raising blood MOTS-c or adding synthetic peptide reverses ageing. It shows that endogenous regulation may differ between circulation and muscle.

What did the human genetics study find?

A mitochondrial DNA variant changes position 14 of the MOTS-c sequence from lysine to glutamine. The variant is often called K14Q, using the one-letter codes for those amino acids.

Researchers analysed three human cohorts containing 27,527 people. A cohort is a defined group whose characteristics or health outcomes are studied. Men carrying the variant had a higher prevalence of type 2 diabetes, while the association was not found in women. In one cohort, the association in men was strongest among those with the lowest physical activity.

The same paper compared the usual and K14Q forms in cells and mice. The variant form produced weaker metabolic effects in those models. Combining human association data with experiments makes the biological question more convincing than either approach alone.

It still does not prove that giving the usual MOTS-c sequence prevents diabetes. Genetic variants are present throughout life and may influence several linked processes. An association can also differ by ancestry, sex, environment or the way physical activity is measured.

Why do biomarker studies sometimes disagree?

A study of lean and obese adults found that plasma MOTS-c was associated with insulin sensitivity in the lean group but not the obese group. Another study found that circulating MOTS-c and a related peptide were positively associated with abdominal and liver fat in people without diabetes. A cardiovascular study reported lower circulating levels in people with impaired function of the inner lining of coronary blood vessels.

These findings do not form a simple pattern in which more MOTS-c is always better. Endogenous levels may rise as a response to metabolic stress in one setting and fall with impaired production or altered clearance in another. Age, sex, timing, fasting state and assay method may also change the measurement.

Reverse causation is another problem. This occurs when a disease process changes the biomarker rather than the biomarker causing the disease. A single blood sample usually cannot establish the direction.

Biomarker research is useful for selecting populations and outcomes for trials. It cannot establish an administration strategy or clinical benefit.

What did Health Canada's November 2026 peptide contamination warning find?

On 12 November 2026, Health Canada reported that laboratory testing had identified *Sphingomonas aquatilis/melonis* bacteria in an injectable peptide product seized from a retailer in Ottawa. The retailer's unauthorised inventory included products labelled MOTS-c. The agency did not say that every product on its inventory list, or every batch of the named compound, tested positive for bacteria.

This is a product-quality and safety finding, not a new clinical trial of the peptide. Bacterial contamination in material intended for injection can cause serious infection, including sepsis. The agency also warned that a label saying 'for research use only' does not demonstrate sterility or make an unauthorised product suitable for human use. The finding cannot be used to estimate contamination rates across the wider market or to judge the quality of material used in controlled clinical studies.

Is MOTS-c approved?

MOTS-c has no FDA-approved medical use. It is not authorised as a medicine by the European Medicines Agency or the UK Medicines and Healthcare products Regulatory Agency.

A registered clinical trial does not create approval. A compound record, research paper or purity certificate also does not establish that a finished product has passed regulatory review.

The FDA has not approved MOTS-c for weight loss, diabetes, fitness, recovery, ageing or any other use. A compounded preparation does not become approved simply because a pharmacy makes it.

FDA's compounding-risk page states that the agency has not identified human exposure data for MOTS-c drug products and highlights possible immune reactions and peptide-related impurities. That describes the agency's stated evidence position. A registered study does not itself supply published exposure or safety results, and CB4211 is a different molecule. The FDA entry appears among substances whose compounding nominations were withdrawn; withdrawal of a nomination is not a finding of safety.

Is MOTS-c prohibited in sport?

Yes. The World Anti-Doping Agency, normally called WADA, names MOTS-c on its 2026 Prohibited List under hormone and metabolic modulators. It is prohibited at all times, both within and outside competition, for athletes governed by the World Anti-Doping Code.

The anti-doping rule is separate from medical approval. A substance can be prohibited in sport without being an approved medicine, and a prescription medicine can also be prohibited under certain conditions.

What is known about side effects?

There is no completed, published clinical programme large enough to define the safety of native MOTS-c administered to people. This means a reliable list of common reactions, uncommon serious events, interactions and long-term risks is not available.

Safety results from CB4211 concern a modified analogue. Side effects reported informally by people using unregulated products cannot show whether the cause was MOTS-c, an impurity, contamination, an incorrect concentration or another substance.

MOTS-c affects basic metabolic and stress-response pathways in experiments. This is a reason for formal safety study, not evidence that the peptide is either dangerous or harmless. Particular uncertainty remains for people with diabetes, cancer, pregnancy, heart disease or medicines affecting glucose and AMPK-related pathways.

Online products add separate risks involving identity, purity, sterility, bacterial toxins and storage history.

Why can safety not be inferred from a natural sequence?

The body producing a peptide does not make every external exposure safe. Insulin, growth hormone and many other natural signals can have important adverse effects when administered as medicines. Timing, concentration, route and duration can all change a biological response.

MOTS-c research involves glucose handling, AMPK and cellular stress. Unwanted effects could therefore depend on food intake, exercise, diabetes medicines, organ function or another illness. These are possibilities that need testing, not a list of established harms.

Repeated administration may also create an immune response to the peptide or to impurities. This is why the MOTS-MET protocol includes anti-drug antibodies and treatment-emergent adverse events. A treatment-emergent adverse event is a new or worsened medical event after the study begins, whether or not investigators decide the product caused it.

A small early trial can identify common short-term problems. It cannot reliably detect an event that occurs once in several thousand exposures, nor can it establish effects after years of use. Pregnancy, breastfeeding, children, older adults with several illnesses and people with substantial liver or kidney impairment remain important evidence gaps.

Safety claims based on online anecdotes have an additional problem: the contents and concentration of the product may be uncertain. A reaction cannot be confidently attributed to MOTS-c when identity, contamination and other substances have not been ruled out.

What benefits are claimed, and what does the evidence support?

ClaimWhat the evidence supports
Improves insulin sensitivityCell and mouse findings are encouraging; a human Phase 2 trial is under way but has no results
Causes weight lossReduced diet-related weight gain was reported in mice; human treatment benefit is not established
Improves exercise performancePerformance improved in treated mice; human research measured the body's own MOTS-c after exercise
Mimics or replaces exerciseNo human trial establishes this claim
Slows ageingFunctional measures improved in old mice, but human anti-ageing benefit and longer lifespan are unproven
Treats fatty liver diseaseCB4211, a modified analogue, had a small early trial; native MOTS-c has not been shown to treat the condition
FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is MOTS-c a peptide?

Yes. It is a chain of 16 amino acids.

Is MOTS-c made by mitochondria?

Its sequence is encoded within mitochondrial DNA. Research proposes that an RNA message is translated into the peptide in the cell cytoplasm.

When was MOTS-c discovered?

It was first described in a peer-reviewed scientific paper published in March 2015.

Does MOTS-c improve exercise performance?

Administered MOTS-c improved several performance measures in mice. A small human study measured increased endogenous MOTS-c after exercise but did not give the peptide to participants.

Does MOTS-c cause weight loss?

Mouse studies reported less diet-related weight gain. No completed human trial establishes MOTS-c as a weight-loss treatment.

Is MOTS-c in human trials?

Yes. A Phase 2a study that began in 2026 is testing native MOTS-c in adults with prediabetes and overweight or obesity. It has not reported results.

Is CB4211 the same as MOTS-c?

No. CB4211 is a modified analogue. Findings from its early trial cannot be transferred directly to native MOTS-c.

Is MOTS-c FDA approved?

No. It has no FDA-approved medical use.

Is MOTS-c banned in sport?

WADA's 2026 Prohibited List names MOTS-c as prohibited at all times for athletes covered by its rules.

How is synthetic MOTS-c made?

It is assembled chemically from protected amino acids, then released from its solid support, purified and checked for identity and purity.

Is MOTS-c safe?

The safety of administered native MOTS-c has not been established in an adequate published human programme.

What the evidence supports today

MOTS-c is an important biological discovery because it expanded the idea of what mitochondrial DNA may encode and how mitochondria may communicate with the rest of the cell.

The treatment evidence is much less advanced than the biological story. Cell studies describe energy-sensing and stress pathways. Mouse experiments report effects on glucose handling, weight gain and physical performance. Human studies have mostly measured endogenous MOTS-c rather than administered it.

The new MOTS-MET trial may begin to answer whether synthetic native MOTS-c changes insulin sensitivity in people. Until results are available, claims about weight loss, fitness, diabetes treatment and longer life remain unproven. The most accurate current description is a recently discovered mitochondrial-derived peptide with substantial preclinical research and early, unfinished human development. The Research Methodology guide explains why registered trials without results cannot be treated as evidence of benefit.

RESEARCH AND MEDICAL NOTICE

This article is educational and does not provide medical advice, dosage recommendations, administration instructions, injection technique, reconstitution, timing, cycling, stacking or purchasing guidance. Animal administration levels are included only to explain published experiments. MOTS-c has no approved medical use and is prohibited under WADA rules for covered athletes.

RESEARCH LIBRARY

Sources

Primary evidenceFDA
FDA compounding-risk assessment for MOTS-cOpen source →
Primary evidencePubMed
Lee et al. Original discovery of MOTS-cOpen source →
Primary evidencePubMed Central
Lee et al. Full text of the 2015 discovery paperOpen source →
Primary evidencePubMed
Kim et al. MOTS-c movement into the nucleus during metabolic stressOpen source →
Primary evidencePubMed
Reynolds et al. MOTS-c, exercise and age-related physical declineOpen source →
Primary evidencePubMed Central
Reynolds et al. Full text of the exercise studyOpen source →
Primary evidencePubMed
D'Souza et al. MOTS-c in muscle and blood across age groupsOpen source →
Primary evidencePubMed Central
D'Souza et al. Full text of the healthy ageing studyOpen source →
Primary evidencePubMed
Woodhead et al. Acute exercise and circulating mitochondrial-derived peptidesOpen source →
Primary evidencePubMed
Zempo et al. MOTS-c K14Q variant in human cohorts and modelsOpen source →
Primary evidencePubMed Central
Zempo et al. Full text of the K14Q studyOpen source →
Primary evidencePubMed
Cataldo et al. Plasma MOTS-c and insulin sensitivityOpen source →
Primary evidencePubMed
Ramanjaneya et al. MOTS-c, abdominal fat and liver fatOpen source →
Primary evidencePubMed
Qin et al. MOTS-c and coronary endothelial functionOpen source →
Primary evidenceClinicalTrials.gov
ClinicalTrials.gov. MOTS-MET Phase 2a study of native MOTS-cOpen source →
Primary evidenceClinicalTrials.gov
ClinicalTrials.gov. CB4211 Phase 1a and 1b studyOpen source →
Primary evidenced1io3yog0oux5.cloudfront.net
CB4211 clinical research posterOpen source →
Primary evidenceWorld Anti-Doping Agency
World Anti-Doping Agency. 2026 Prohibited ListOpen source →
Primary evidenceUSADA
US Anti-Doping Agency. MOTS-c athlete guidanceOpen source →
Primary evidenceFDA
FDA update on generic peptide quality guidance and withdrawal of the 2021 guidanceOpen source →

Research reviewed through 17 November 2026.